Remarkably, in a patient who cannot tolerate T cell activation (due to risk of graft failure), local injection of the potent T cell activator IL-2 was sufficient to maximize the anti-tumor immune response and did not cause any further toxicities. Here, IL2 is linked to neoplasm.